Study to Evaluate Response Rates in CHC [chronic hepatitis C] Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders.
Phase of Trial: Phase IV
Latest Information Update: 11 Apr 2017
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 08 Feb 2011 Planned end date changed from 1 Jun 2011 to 1 Oct 2009 as reported by ClinicalTrials.gov.
- 15 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2007 New trial record.